MG
INBX

Michael Gelband’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Michael Gelband’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,958
Closed -$201K – 2187
2023
Q3 		$201K Buy
+10,958
New +$229K ﹤0.01% 1524
2022
Q3 		– Sell
-67,233
Closed -$763K – 2517
2022
Q2 		$763K Buy
+67,233
New +$989K 0.01% 1191
2020
Q4 		– Sell
-14,115
Closed -$254K – 2599
2020
Q3 		$254K Buy
+14,115
New +$256K 0.01% 1368

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Michael Gelband's INBX Position: Q4 2023 in Review

Michael Gelband sold out of Inhibrx, Inc. Common Stock (INBX) in Q4 2023, closing a stake of 10,958 shares — an estimated $201K sold.

Michael Gelband first reported a position in INBX in Q3 2020 and held it in 3 quarters. The position peaked at $763K in Q2 2022. 127 funds tracked by Wall St. Rank hold INBX as of Q4 2023.

  • Michael Gelband reported no remaining Inhibrx, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Michael Gelband sold 10,958 Inhibrx, Inc. Common Stock shares in Q4 2023, an estimated $201K.
  • Michael Gelband first reported a position in Inhibrx, Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Michael Gelband's Inhibrx, Inc. Common Stock position peaked at $763K in Q2 2022.
  • 127 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q4 2023.

Based on ExodusPoint Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.